MX2020007959A - Derivados de 2h-indazol e inhibidores de cdk4 y cdk6 y sus usos terapeuticos. - Google Patents

Derivados de 2h-indazol e inhibidores de cdk4 y cdk6 y sus usos terapeuticos.

Info

Publication number
MX2020007959A
MX2020007959A MX2020007959A MX2020007959A MX2020007959A MX 2020007959 A MX2020007959 A MX 2020007959A MX 2020007959 A MX2020007959 A MX 2020007959A MX 2020007959 A MX2020007959 A MX 2020007959A MX 2020007959 A MX2020007959 A MX 2020007959A
Authority
MX
Mexico
Prior art keywords
sup
therapeutic uses
cdk4
cyclin
prodrugs
Prior art date
Application number
MX2020007959A
Other languages
English (en)
Inventor
Michael Nicholas Greco
Jirong Peng
Don Zhang
Michael John Costanzo
Original Assignee
Beta Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beta Pharma Inc filed Critical Beta Pharma Inc
Publication of MX2020007959A publication Critical patent/MX2020007959A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se divulgan compuestos 2H-indazol 2-aminopirimidina sustituidos de la fórmula (I), (ver Fórmula) donde R1 es hidrogeno y su profármaco, donde R1 es un grupo metabolizable en condiciones fisiológicas, como inhibidores de cinasa dependiente de ciclina (CDK) y de la proliferación celular y los usos terapéuticos y métodos de preparación de ellos. Estos compuestos y las sales farmacéuticamente aceptables, solvatos, profármacos y composiciones farmacéuticas de ellos, son útiles para el tratamiento de enfermedades y trastornos asociados con la actividad de las cinasas dependientes de ciclina, en particular CDK4/6, que incluyen en forma no taxativa diversos canceres y enfermedades o afecciones con la inflación.
MX2020007959A 2018-01-29 2019-01-29 Derivados de 2h-indazol e inhibidores de cdk4 y cdk6 y sus usos terapeuticos. MX2020007959A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862623516P 2018-01-29 2018-01-29
PCT/US2019/015547 WO2019148161A1 (en) 2018-01-29 2019-01-29 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
MX2020007959A true MX2020007959A (es) 2020-09-18

Family

ID=67394794

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007959A MX2020007959A (es) 2018-01-29 2019-01-29 Derivados de 2h-indazol e inhibidores de cdk4 y cdk6 y sus usos terapeuticos.

Country Status (15)

Country Link
US (1) US11352341B2 (es)
EP (1) EP3746072B1 (es)
JP (1) JP7337395B2 (es)
KR (1) KR20200115583A (es)
CN (1) CN111989099A (es)
AU (1) AU2019211491B2 (es)
BR (1) BR112020015405A2 (es)
CA (1) CA3088381A1 (es)
EA (1) EA202091450A1 (es)
IL (1) IL275948A (es)
MX (1) MX2020007959A (es)
PH (1) PH12020551155A1 (es)
SG (1) SG11202006748RA (es)
TW (1) TW201940166A (es)
WO (1) WO2019148161A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020000962A2 (pt) 2017-07-18 2020-07-14 Nuvation Bio Inc. compostos de 1,8-naftiridinona e usos dos mesmos
EP3654978A4 (en) 2017-07-18 2021-03-31 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AS ADENOSIN ANTAGONISTS
EP3752491A4 (en) 2018-02-15 2021-12-01 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS
BR112020025661A2 (pt) * 2018-06-18 2021-03-23 UCB Biopharma SRL antagonista anti-grem1, agente anticâncer, métodos de tratamento de um câncer e de prognosticar um câncer, composição ou kit, métodos para a detecção de câncer, para determinar se um paciente com ou com suspeita de ter ou com risco de desenvolver câncer é ou não susceptível de responder ao tratamento com um agente quimioterápico, e para determinar se um paciente com ou com suspeita de ter ou com risco de desenvolver câncer tem probabilidade de responder ao tratamento com um antagonista de grem1
US11254670B2 (en) 2019-01-18 2022-02-22 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
MX2021008650A (es) 2019-01-18 2021-11-03 Nuvation Bio Inc Compuestos heterociclicos como antagonistas de adenosina.
EP3917532A4 (en) * 2019-01-29 2022-09-28 Beta Pharma, Inc. 2H-INDAZOLE DERIVATIVES USED AS THERAPEUTIC AGENTS AGAINST BRAIN CANCERS AND BRAIN METASTASIS
CN114364675A (zh) * 2019-05-05 2022-04-15 上海齐鲁锐格医药研发有限公司 Cdk抑制剂
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060111716A (ko) 2002-01-22 2006-10-27 워너-램버트 캄파니 엘엘씨 2-(피리딘-2-일아미노)-피리도[2,3-ｄ]피리미딘-7-온
PT1648889E (pt) 2003-07-11 2008-12-10 Warner Lambert Co Sal isetionato de um inibidor selectivo da cdk4
CN1956982A (zh) 2004-05-21 2007-05-02 万有制药株式会社 具有氨基噻唑骨架的Cdk4、6选择性抑制剂
TWI398252B (zh) 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
WO2009061345A2 (en) * 2007-11-07 2009-05-14 Cornell Research Foundation, Inc. Targeting cdk4 and cdk6 in cancer therapy
ME01282B (me) 2008-08-22 2013-06-20 Novartis Ag Jedinjenja pirolopirimidina kao inhibitori cdk
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
AU2014375500B2 (en) 2013-12-31 2017-03-16 Xuanzhu Biopharmaceutical Co., Ltd. Kinase inhibitor and use thereof
MY187555A (en) * 2014-07-24 2021-09-29 Beta Pharma Inc 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
CN111333627A (zh) 2015-03-11 2020-06-26 正大天晴药业集团股份有限公司 作为抗癌药物的取代的2-氢-吡唑衍生物
CN107286134B (zh) 2016-04-11 2019-04-12 上海勋和医药科技有限公司 2，4-二取代嘧啶衍生物作为cdk抑制剂及其应用

Also Published As

Publication number Publication date
JP7337395B2 (ja) 2023-09-04
CN111989099A (zh) 2020-11-24
EA202091450A1 (ru) 2021-01-14
JP2021512161A (ja) 2021-05-13
US20210139459A1 (en) 2021-05-13
AU2019211491B2 (en) 2024-03-14
PH12020551155A1 (en) 2021-06-07
EP3746072B1 (en) 2023-04-12
KR20200115583A (ko) 2020-10-07
AU2019211491A1 (en) 2020-07-30
CA3088381A1 (en) 2019-08-01
EP3746072A4 (en) 2021-06-02
EP3746072A1 (en) 2020-12-09
TW201940166A (zh) 2019-10-16
WO2019148161A1 (en) 2019-08-01
US11352341B2 (en) 2022-06-07
SG11202006748RA (en) 2020-08-28
BR112020015405A2 (pt) 2020-12-08
IL275948A (en) 2020-08-31

Similar Documents

Publication Publication Date Title
MX2020007959A (es) Derivados de 2h-indazol e inhibidores de cdk4 y cdk6 y sus usos terapeuticos.
PH12017500146A1 (en) 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
ECSP22011086A (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2022012306A (es) Inhibidores alostericos de cromenona del fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades.
AR066214A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas. usos y composiciones farmaceuticas
NZ708563A (en) Treatment of cancers using pi3 kinase isoform modulators
NO20051265L (no) Anvendelse av og noen nye imidazopyridiner
TW201613593A (en) Molecules for administration to ROS1 mutant cancer cells
CN115057855B (zh) 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
UA99141C2 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
MY141220A (en) Pyrazole derivatives as inhibitors of receptor tyrosine kinases
JP2010527981A (ja) 癌処置用のｃｈｋ阻害剤およびｐａｒｐ阻害剤の組み合わせ剤
GB201302704D0 (en) Therapeutic compounds
SG11201806438UA (en) Fused Pyrazole Derivatives, Preparation Method Thereof, And Use Thereof In Treatment Of Cancers, Inflammation And Immune Diseases
CR20230517A (es) Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
MX2023006145A (es) Inhibidores de prmt5 novedosos.
MX2018013325A (es) Derivados de adenina como inhibidores de proteína quinasa.
MX2013008870A (es) Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazoli n-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion.
JOP20210324A1 (ar) مشتقات من 2h-indazole واستخدامها في علاج مرض
CO2022008606A2 (es) Derivados de piridopirimidinona como antagonistas de ahr
NZ761680A (en) Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors
CR20220160A (es) Derivados de piridazin-3(2h)-ona fusionados con azol
CL2019002601A1 (es) Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos.
MX2020009738A (es) Derivados de imidazolidin-2-ona sustituidos como inhibidores de prmt5.